Logo image of PPCB

PROPANC BIOPHARMA INC (PPCB) Stock Fundamental Analysis

NASDAQ:PPCB - Nasdaq - US74346N7012 - Common Stock - Currency: USD

2.87  +2.87 (+Infinity%)

After market: 3.55 +0.68 (+23.69%)

Fundamental Rating

0

Taking everything into account, PPCB scores 0 out of 10 in our fundamental rating. PPCB was compared to 551 industry peers in the Biotechnology industry. Both the profitability and financial health of PPCB have multiple concerns. PPCB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PPCB has reported negative net income.
PPCB had a negative operating cash flow in the past year.
In the past 5 years PPCB always reported negative net income.
PPCB had a negative operating cash flow in each of the past 5 years.
PPCB Yearly Net Income VS EBIT VS OCF VS FCFPPCB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

With a Return On Assets value of -2147.26%, PPCB is not doing good in the industry: 97.46% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -2147.26%
ROE N/A
ROIC N/A
ROA(3y)-3739.99%
ROA(5y)-6299.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PPCB Yearly ROA, ROE, ROICPPCB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PPCB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PPCB Yearly Profit, Operating, Gross MarginsPPCB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

PPCB has more shares outstanding than it did 1 year ago.
The debt/assets ratio for PPCB is higher compared to a year ago.
PPCB Yearly Shares OutstandingPPCB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
PPCB Yearly Total Debt VS Total AssetsPPCB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 500K 1M 1.5M

2.2 Solvency

PPCB has an Altman-Z score of -1311.85. This is a bad value and indicates that PPCB is not financially healthy and even has some risk of bankruptcy.
PPCB has a worse Altman-Z score (-1311.85) than 96.92% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1311.85
ROIC/WACCN/A
WACCN/A
PPCB Yearly LT Debt VS Equity VS FCFPPCB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 -1M -2M -3M

2.3 Liquidity

A Current Ratio of 0.00 indicates that PPCB may have some problems paying its short term obligations.
PPCB's Current ratio of 0.00 is on the low side compared to the rest of the industry. PPCB is outperformed by 97.64% of its industry peers.
A Quick Ratio of 0.00 indicates that PPCB may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.00, PPCB is doing worse than 97.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0
Quick Ratio 0
PPCB Yearly Current Assets VS Current LiabilitesPPCB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 98.43% over the past year.
EPS 1Y (TTM)98.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PPCB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PPCB Price Earnings VS Forward Price EarningsPPCB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PPCB Per share dataPPCB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -200 -400 -600

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PPCB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROPANC BIOPHARMA INC

NASDAQ:PPCB (8/15/2025, 8:00:01 PM)

After market: 3.55 +0.68 (+23.69%)

2.87

+2.87 (+Infinity%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners7.75%
Inst Owner ChangeN/A
Ins Owners71.48%
Ins Owner Change0%
Market Cap33.32M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-703.62
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS-0.36
TBVpS-0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2147.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3739.99%
ROA(5y)-6299.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0
Quick Ratio 0
Altman-Z -1311.85
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.4%
OCF growth 3YN/A
OCF growth 5YN/A